Regeneron Pharmaceuticals Inc (REGN)
Interest coverage
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 4,272,300 | 4,448,500 | 4,845,000 | 4,719,500 | 4,918,200 | 6,093,600 | 6,399,300 | 9,190,200 | 9,383,100 | 8,105,000 | 7,298,800 | 4,460,200 | 3,867,300 | 3,524,400 | 3,276,100 | 2,580,200 | 2,459,300 | 2,246,400 | 2,113,400 | 2,543,700 |
Interest expense (ttm) | US$ in thousands | 73,000 | 72,100 | 69,600 | 63,800 | 59,400 | 56,100 | 55,000 | 56,300 | 57,300 | 58,000 | 70,100 | 65,400 | 56,900 | 48,800 | 30,300 | 28,600 | 30,200 | 30,900 | 30,500 | 29,400 |
Interest coverage | 58.52 | 61.70 | 69.61 | 73.97 | 82.80 | 108.62 | 116.35 | 163.24 | 163.75 | 139.74 | 104.12 | 68.20 | 67.97 | 72.22 | 108.12 | 90.22 | 81.43 | 72.70 | 69.29 | 86.52 |
December 31, 2023 calculation
Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $4,272,300K ÷ $73,000K
= 58.52
The interest coverage ratio of Regeneron Pharmaceuticals, Inc. provides insights into the company's ability to cover its interest expenses with its operating income.
Looking at the data provided, the interest coverage ratio for the last four quarters has not been explicitly mentioned for Q4 2023, Q3 2023, Q2 2023, and Q1 2023. However, it is observed that in the previous quarters, the interest coverage ratio was relatively high, with values of 114.81 in Q3 2022, 128.45 in Q2 2022, and 161.72 in Q1 2022.
A high interest coverage ratio indicates that the company is generating significantly more operating income than is required to cover its interest expenses. This suggests that Regeneron Pharmaceuticals, Inc. has a strong ability to meet its interest obligations with its current level of earnings.
While it is unknown how the interest coverage ratio has trended in the recent quarters due to lack of data, the historically high ratios from the previous quarters imply a favorable financial position in terms of managing interest payments. Further monitoring of this ratio in subsequent quarters would provide a more comprehensive understanding of the company's financial health and its ability to withstand interest rate fluctuations.
Peer comparison
Dec 31, 2023
See also:
Regeneron Pharmaceuticals Inc Interest Coverage (Quarterly Data)